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INTRODUCTION
Growth hormone (GH) is secreted by the anterior pituitary 
gland and plays an important role in maintaining body 
composition, well-being, physical performance, and 
cardiovascular health in adults as well as children.[1,2] These 
features have led to its misuse by professional sportsmen 
and women who wish to improve their athletic 
performance.[3] GH use was prohibited by the International 
Olympic Committee (IOC) in 1989 and it appears on 
the current World Anti-Doping Agency (WADA) list of  
prohibited substances.[4] The true prevalence of  GH misuse 
is unknown because of  the secrecy that surrounds its 
misuse but there are suffi cient high profi le cases to suggest 
that the scale of  misuse warrants the concern of  WADA. It 
is unclear when GH was fi rst used to enhance performance 
but “The Underground Steroid Handbook” was the earliest 
publication to describe the potential benefi cial effects of  
GH,[5] at least 10 years before clinical endocrinologists 
started treating adults with GH defi ciency.[6,7]
This review will examine whether GH is performance 
enhancing properties and will discuss the challenges 
involved in the detection of  exogenous GH administration 
and the work undertaken to develop a robust test to detect 
its misuse.
WHY ATHLETES MISUSE GH?
Exercise depends on an adequate supply of  nutrients 
and oxygen to the muscle fi bers. Glucose for short-term 
high-intensity activity and free fatty acids (FFAs) for 
more prolonged activity are combusted to release kinetic 
energy. GH has a number of  effects on protein anabolism 
and intermediate metabolism that may improve exercise 
performance through increased fuel and oxygen delivery 
to exercising muscle, increased muscle strength or any 
combination of  these factors.[8] In addition, it may improve 
cardiovascular function[9,10] and thermoregulation.[11]
The potent physiological actions of  GH have been 
demonstrated through a series of  randomized controlled 
trials of  GH replacement in people with GH defi ciency. 
Prior to treatment, adults with GH defi ciency lose lean 
tissue while accumulating fat, in particular visceral fat.[12,13] 
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A B S T R A C T
Athletes have been misusing growth hormone (GH) for its anabolic and metabolic effects since the early 1980s, at least a decade before 
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Skeletal muscle mass and strength[14-16] is reduced with a 
consequent impairment of  physical performance, exercise 
capacity, and VO2 max (aerobic capacity or the maximum 
ability to take in and use oxygen).[17] Following treatment 
with recombinant human GH (rhGH), body composition 
normalizes[6,7] and physical performance improves.[18]
It does not necessarily follow, however, that the 
administration of  supraphysiological GH doses will lead to 
further performance advantage in healthy adults. Indeed the 
opposite is suggested by acromegaly, which is characterized 
by marked abnormalities in protein and carbohydrate 
metabolism,[19,20] muscle weakness rather than excessive 
strength,[21] and cardiomyopathy.[22] A systematic review 
of  44 articles describing 27 studies reported that although 
GH administration was associated with increase in lean 
body mass and decrease in fat mass, it did not improve a 
number of  measures of  performance.[23]
Most recently trials have begun to show a performance 
benefi t for GH. The fi rst was undertaken in abstinent 
anabolic steroid users and demonstrated significant 
improvements in strength, peak power output, and VO2 max 
as well as the expected changes in body composition.[24] It 
is possible that the prior use of  steroids may have rendered 
the athletes particularly sensitive to the anabolic actions 
of  GH. A further randomized, placebo-controlled trial of  
6-weeks’ treatment with rhGH demonstrated a short-lived 
improvement in sprint capacity in both men and women 
with GH and a synergistic effect with testosterone in men.[25]
POTENTIAL ADVERSE EFFECTS OF GH 
MISUSE
The side effects associated with GH administration in 
GH defi ciency are well-documented and may affect any 
athlete receiving GH;[26] however, as anecdotal evidence 
suggests that many athletes are taking much higher doses 
than those used therapeutically, it is possible that features 
of  acromegaly may become apparent with prolonged use. 
Additional long-term effects may include fl uid retention, 
which may lead to ankle swelling, hypertension, headache, 
diabetes, and cardiomyopathy. There is also a potential 
for increased risk of  certain cancers; including colorectal, 
thyroid, breast, and prostate cancer.[27] Cadaveric GH, with 
its attendant risk of  the prion-induced Creutzfeldt-Jakob 
disease, is still available in the black market.[28]
CHALLENGES IN THE DETECTION OF GH 
MISUSE
Detecting the misuse of  exogenous GH poses a formidable 
challenge for several reasons.[3] rhGH has an identical amino 
acid sequence to the native 22-kDaisoform of  the hormone, 
while cadaveric GH is indistinguishable from endogenous GH. 
It has a short half-life (<20 min) and is secreted in a pulsatile 
manner leading to widely varying circulating GH concentration 
throughout the day. Exercise and stress are potent stimulators 
of  GH secretion[29,30] and so high GH concentrations in the 
post-competition setting would be expected.
DEVELOPMENT OF A TEST TO DETECT GH 
MISUSE
Two different yet complementary approaches have been 
investigated to detect GH misuse; the fi rst, pioneered 
by Christian Strasburger, Martin Bidlingmaier and Zida 
Wu in Germany, is based on the detection of  different 
pituitary GH isoforms, while the second, which was 
developed by the GH-2000 and GH-2004 teams, utilizes 
the measurement of  GH-sensitive markers.
THE ISOFORM METHOD
Endogenous pituitary GH occurs in multiple isoforms 
of  which 70% is in the form of  a 22 kDa polypeptide.[31] 
By contrast, rhGH comprises solely the 22-kDa isoform. 
When rhGH is administered, endogenous pituitary 
secretion is downregulated through negative feedback and 
the concentration of  non-22-kDa isoforms is suppressed. 
The isoform method relies on the measurement of  the 
ratio of  22 kDa GH to total GH.[32]
The proportions of  GH isoforms are unaffected by age, 
sex, sporting discipline, and pathological states,[33,34] but 
exercise causes a transient relative increase in the 22-kDa 
isoform, thereby reducing the sensitivity of  the test if  
samples are taken immediately after competition.[35,36] This 
method was introduced prior to the 2004 Athens Olympic 
Games and subsequently improved when the assays used 
for the method were commercialized.[37]
After testing over 1,000 samples, the fi rst adverse analytical 
fi nding came in February 2010 when the British Rugby 
League player, Terry Newton, tested positive.[38] Since then, 
several other positive tests have been reported including the 
announcement in September 2010 from the Canadian Center 
for Ethics in Sport that Matt Socholotiuk, a University of  
Waterloo football player, had tested positive for GH use on 
31 March 2010.[39] The following year, Colorado Sky Sox 
fi rst baseman Mike Jacobs became the fi rst baseball player 
to test positive for GH and was subsequently suspended 
for 50 games by Minor League Baseball.[40]
In 2011, Andrus Veerpalu, an Estonian Olympic gold 
medal winning skier, tested positive for GH. However, he 
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pleaded his innocence and challenged the laboratory fi nding 
in the Court of  Arbitration for Sport who subsequently 
acquitted Veerpalu on 25 March 2013 as the court was not 
convinced that the threshold for considering an adverse 
analytical fi nding was suffi ciently reliable to uphold the 
doping conviction; nevertheless, the court stated “that there 
are many factors in this case which tend to indicate that the 
Athlete did in fact himself  administer exogenous hGH”.[41]
The Achilles’ heel of  the isoform method is its short 
window of  detection.[42] Recombinant GH, even when 
injected subcutaneously, is cleared rapidly and GH is 
frequently undetectable in a blood sample taken the 
morning after an injection,[43] while spontaneous GH 
secretion returns to normal within 48 h of  the last dose 
of  rhGH.[44] Consequently, any athlete who ceases GH 
several days prior to a competition will not be detected. 
As such, the optimal use of  this method is likely to be in 
unannounced ‘out of  competition’ testing, as happened 
in the case of  Terry Newton. A further disadvantage of  
this method is that it will not detect the use of  cadaveric 
GH or GH secretagogues as these do not alter the isoform 
profi le.
THE GH-2000 MARKER METHOD
The GH-2000 marker method measures two serum proteins, 
insulin-like growth factor-I (IGF-I) and N-terminal propeptide 
of  type III procollagen (P-III-NP), both of  which increase in 
a dose-dependent manner in response to GH administration 
and therefore act as “markers” of  GH administration. This 
method was fi rst conceived by Peter Sönksen who established 
the large multicenter GH-2000 project, with funding from 
the European Union under their BIOMED 2 initiative, the 
International Olympic Committee and GH manufacturers 
Novo Nordisk and Pharmacia. Initially, 25 potential markers 
of  GH action were considered;[45,46] but IGF-I and P-III-NP 
were chosen for the GH-2000 test because these provided 
the best discrimination between individuals receiving GH 
or placebo during a 28-day randomized controlled GH 
administration trial.[47] Both IGF-I and P-III-NP have little 
diurnal or day-to-day variation, low intraindividual variation[48] 
and only change minimally in response to exercise.[45,46] The 
markers are used in conjunction with the use of  gender 
specifi c equations, “discriminant functions”, to improve 
the sensitivity and specifi city of  the test compared with 
single-marker analysis [Table 1].[47] The markers decline with 
age as endogenous GH secretion declines and a factor relating 
to the inverse of  age is also included in the formulae.[49]
Although the principle of  the method was approved at an 
IOC workshop in Rome in March 1999,[50] further work 
has been needed to ensure that a number of  confounding 
factors including ethnicity,[51,52] injury,[53] sporting 
discipline,[49,54] exercise,[45,46,55] and body habitus[49,54] would 
not invalidate the test. The test has subsequently been 
validated in independent laboratories in Germany[56] and 
Australia.[57]
Although IGF-I and P-III-NP are more stable than GH, 
the markers still exhibit a wide interindividual variability 
that could mean that those with lower baseline marker 
concentrations are potentially harder to catch. Within 
individuals, however, there is much less variability which 
raises the possibility of  the use of  a biological “athlete 
passport” or “profi ling” to improve the test sensitivity.[48]
The test was introduced at the London Olympic and 
Paralympic games which led to the disqualifi cation of  
Nikolay Marfi n and Vadim Rakitin, two Russian powerlifters, 
who admitted to misusing GH after an adverse analytical 
fi nding.[58]
CONCLUSION
It is widely believed that athletes are misusing GH for its 
anabolic and metabolic effects. Recent studies suggest 
that GH has a modest performance benefi t in amateur 
athletes, particularly when combined with anabolic 
steroids. Over the last decade, there have been major 
advances in methodologies to detect GH and this should 
mean that athletes will no longer be able to take GH 
with impunity.
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−8.459+2.454*log (P-III-NP) + 2.195*log (IGF-I)-73.666/age
GH: Growth hormone, P-III-NP: N-terminal propeptide of type III procollagen, IGF: 
Insulin-like growth factor, Log: Natural logarithm
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